Objectives: To evaluate BLyS as biomarker in disease activity in urinary sample and renal biopsy from patients with LN. Methods: Retrospective study. Between June 2009 and October 2013, 32 patients with SLE and LN fullfilling SLE classification criteria of ACR 1997 were included. The renal biopsies were evaluated according to the ISN/RPS classification system. The gene expression levels of BLyS were quantified using Quantitative Real Time PCR (QPCR). The relative quantification method was used for analysis, where Ct was normalized to an endogenous control β2Microglobulina (β2M) ( Ct BLyS). The data expressed as Ct are inversely proportional to gene expression level. The value of BLyS is expressed as median (M) and interquartile range (IQR) for filing a non-normal distribution. Results: 26 (81.3%) patients were female with a mean age at diagnosis of 26.9±13 years and 31.9±29 years at the time of renal biopsy. The SLEDAI at the time of biopsy was 10.5 (IQR 0-15.7) and SLICC ≥1 in 13 (32.5%), hypocomplementemia 13/31 (41.9%) and positive DNA in 11/29 (37.9%) patients. Biopsies from patients with proteinuria ≥0.5 and renal failure (RF) (n=23, 71.9%), proteinuria isolated (n=14, 43.8%), LN remission. The value of the BLyS gene expression in renal biopsy was 8.09 ) and BLyS in urinary sample was 6.45 Background: Osteonecrosis of the femoral head (ONF) occurs frequently (3-40%) in patients who receive corticosteroid therapy for SLE. MRI can accurately visualize pathological abnormalities of the femoral head, being much more sensitive than plain radiography. To analyze the risk factors associated with steroid-induced ONF, the best approach would be to examine early changes in the femoral head using MRI and any early clinical events attributable to steroid therapy. For treatment of SLE, a number of strategies may be selected according to the clinical conditions of patients, and treatments may differ slightly among hospitals. Therefore, for better clarification of the background factors associated with ONF, the optimum approach would be to analyze the treatment strategy, selection of steroid, initial dose of steroid and drugs used together with steroid in a cohort of patients treated at a single hospital. Objectives: To clarify the factors related to silent ONF in patients with SLE treated at a single institution. Methods: One hundred six patients (12 males and 94 females) with SLE were selected on the basis of having been newly diagnosed and requiring high-dose prednisolone, including pulse therapy with methylprednisolone, as the initial treatment. All the patients initially underwent plain radiography and MRI at the start of corticosteroid treatment to detect any early changes in the femoral head, and subsequent examinations were performed three months later. Laboratory parameters were evaluated at the start of steroid treatment and one month
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